COMMUNIQUÉS West-GlobeNewswire

Standard BioTools Appoints Alex Kim as Chief Financial Officer

07/11/2024 - 14:00

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced the appointment of Alex Kim as Chief Financial Officer, [...]

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

07/11/2024 - 14:00

Data further confirms Company’s “Pulse-Prime” hypothesis NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company [...]

Spur Therapeutics to Participate in B. Riley Securities’ Next-Gen Tissue Delivery Modalities Virtual Summit

07/11/2024 - 14:00

LONDON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced that Michael Parini, Chief Executive Officer of Spur Therapeutics, and Henning Stennicke, Chief Scientific Officer of Spur Therapeutics, will [...]

Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress

07/11/2024 - 14:00

Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) Results show robust [...]

Mesa Labs Announces Second Quarter Results

07/11/2024 - 14:00

LAKEWOOD, Colo., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced [...]

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

07/11/2024 - 14:05

Conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today [...]

Trading statement 9M 2024

07/11/2024 - 07:59

Organic pro forma sales growth of 9%, including 11% in the third quarter. Full-year organic sales growth outlook now expected at the upper end of the 7-8% range and the adjusted EBITDA margin confirmed between 35.5-36.5 [...]

Q3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8%

07/11/2024 - 08:02

Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance has led [...]

Oculis Reports Q3 2024 Financial Results and Provides Company Updates

07/11/2024 - 10:00

Significant advancement on product portfolio, including enrollment in the OCS-01 DIAMOND Phase 3 program in DME and OCS-05 Phase 2 ACUITY trial in acute optic neuritis (AON) with topline readout anticipated in December [...]

Oculis Reports Q3 2024 Financial Results and Provides Company Updates

07/11/2024 - 10:00

ZUG, Switzerland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Significant advancement on product portfolio, including enrollment in the OCS-01 DIAMOND Phase 3 program in DME and OCS-05 Phase 2 ACUITY trial in acute optic neuritis [...]

PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop

07/11/2024 - 04:35

Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory MENLO PARK, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s [...]

Zealand Pharma Announces Financial Results for the First Nine Months of 2024

07/11/2024 - 07:00

Company announcement – No. 49 / 2024 Zealand Pharma Announces Financial Results for the First Nine Months of 2024 Continued strong progress across obesity pipeline with proprietary assets ready for Phase 2 backed by a [...]

Valneva publie ses résultats financiers pour les neuf premiers mois de l’exercice 2024 et fait un point sur ses activités

07/11/2024 - 07:00

Principaux éléments financiers pour les neuf premiers mois de l’exercice 2024 Chiffre d’affaires total de 116,6 millions d’euros comprenant des ventes de produits de 112,5 millions d’euros Bénéfice net de 24,7 millions [...]

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

07/11/2024 - 07:00

Nine-Month Key Financial Highlights Total revenues of €116.6 million, including product sales of €112.5 million Net Profit of €24.7 million, including proceeds from the Priority Review Voucher (PRV) 1 sale Operating [...]

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

06/11/2024 - 22:30

Company implementing 42% reduction in force and resizing its Board of Directors to six seats from ten SAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision [...]

MacroGenics to Participate in Upcoming Investor Conferences

06/11/2024 - 22:30

ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics [...]

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

06/11/2024 - 22:30

Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to SCYNEXIS, received in [...]

Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

06/11/2024 - 22:30

DEER PARK, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]

STERIS Announces Financial Results for Fiscal 2025 Second Quarter

06/11/2024 - 22:30

Total revenue from continuing operations increased 7%; constant currency organic revenue grew 7% As reported diluted EPS from continuing operations increased to $1.51; adjusted EPS increased to $2.14 Fiscal 2025 outlook [...]